Why Is TEMPUS AI INC A (TEM) Stock Moving Today?

Tempus AI Inc. (TEM) stock is moving today after the company announced a $1.5 billion all-stock acquisition of cancer-monitoring firm Personalis. The deal, which expands Tempus’ oncology testing portfolio, has drawn attention from investors and analysts. The stock is reacting to the strategic move into minimal residual disease detection, a growing segment in the precision oncology market.

What Happened

Tempus AI is acquiring Personalis, a firm known for its NeXT Personal cancer detection test, in a stock transaction that values the company at $1.5 billion. The acquisition is intended to integrate Personalis’ minimal residual disease (MRD) test into Tempus’ broader oncology offerings. The deal was disclosed in a recent SEC 8-K filing and has been covered by multiple news outlets, including Quartz, Yahoo Finance, and Seeking Alpha. The move aligns with growing industry interest in blood-based cancer tests and positions Tempus to address a market estimated at $20 billion for MRD detection. However, the stock’s performance has been mixed, with some reports noting that shares have fallen following the announcement.

What The Data Shows

Tempus AI has a market cap of $9.4 billion and is currently unprofitable, with an EPS of -1.72 for the trailing twelve months. Revenue has grown by 69.8% TTM, but the company’s net margin remains negative at -22.2%. The stock has traded between $41.73 and $104.32 over the past 52 weeks. Recent insider transactions show 13 sales totaling $23.3 million in the last 90 days, with no insider purchases. Congressional trades include a recent $15,001, $50,000 purchase by Donald J. Trump on May 22, 2026. Retail traders on social media have speculated on a $16.25 per share price target, but these are not official analyst estimates.

What To Watch

The company has no upcoming earnings date listed. Investors should monitor the broader market reaction to the acquisition, as well as any changes in analyst coverage or regulatory developments.